Taken together, these results suggest that ER+ BC patients whose disease progressed on AI-monotherapy and with tumors expressing high CDK6, p-CDK2 and/or cyclin E1 may not benefit from the sequential treatment of CDK4/6i and ET, and that incorporation of CDK2i in this combination is required. This evidence concerns the gene CDK4 and breast cancer.